Stephen J.  DeNelsky net worth and biography

Stephen DeNelsky Biography and Net Worth

Director of Harvard Bioscience

Stephen DeNelsky serves as a member of the Board of Directors and a member of the Nominating and Governance Committee.

Mr. DeNelsky has more than 30 years of leadership experience in the research, analysis, and valuation of public and private equities in the healthcare industry. He currently serves as a Managing Director at Oaktree Capital Management and was previously a Managing Director at Marathon Asset Management and President at Life Sciences Alternative Funding. Mr. DeNelsky also brings strong board experience and currently serves on the board of Visioncare Inc and previously served on the boards of Integrated Diagnostics and AMICAS, Inc.

Mr. DeNelsky received a B.A. in Economics from the American University and an M.B.A. from the University of Maryland.

What is Stephen J. DeNelsky's net worth?

The estimated net worth of Stephen J. DeNelsky is at least $167.16 thousand as of March 17th, 2026. Mr. DeNelsky owns 21,000 shares of Harvard Bioscience stock worth more than $167,160 as of September 27th. This net worth approximation does not reflect any other investments that Mr. DeNelsky may own. Learn More about Stephen J. DeNelsky's net worth.

How do I contact Stephen J. DeNelsky?

The corporate mailing address for Mr. DeNelsky and other Harvard Bioscience executives is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. Harvard Bioscience can also be reached via phone at (508) 893-8999 and via email at [email protected]. Learn More on Stephen J. DeNelsky's contact information.

Has Stephen J. DeNelsky been buying or selling shares of Harvard Bioscience?

Stephen J. DeNelsky has not been actively trading shares of Harvard Bioscience during the last ninety days. Most recently, on Tuesday, March 17th, Stephen J. DeNelsky bought 10,000 shares of Harvard Bioscience stock. The stock was acquired at an average cost of $4.87 per share, with a total value of $48,700.00. Following the completion of the transaction, the director now directly owns 21,000 shares of the company's stock, valued at $102,270. Learn More on Stephen J. DeNelsky's trading history.

Who are Harvard Bioscience's active insiders?

Harvard Bioscience's insider roster includes Stephen DeNelsky (Director), John Duke (President and Chief Executive Officer), and James Green (CEO). Learn More on Harvard Bioscience's active insiders.

Are insiders buying or selling shares of Harvard Bioscience?

During the last twelve months, Harvard Bioscience insiders bought shares 4 times. They purchased a total of 36,000 shares worth more than $177,353.50. The most recent insider tranaction occured on March, 17th when Director William Snider bought 8,475 shares worth more than $41,103.75. Insiders at Harvard Bioscience own 17.0% of the company. Learn More about insider trades at Harvard Bioscience.

Information on this page was last updated on 3/17/2026.

Stephen J. DeNelsky Insider Trading History at Harvard Bioscience

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2026Buy10,000$4.87$48,700.0021,000View SEC Filing Icon  
See Full Table

Stephen J. DeNelsky Buying and Selling Activity at Harvard Bioscience

This chart shows Stephen J. DeNelsky's buying and selling at Harvard Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Harvard Bioscience Company Overview

Harvard Bioscience logo
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Read More

Today's Range

Now: $7.96
Low: $7.92
High: $8.05

50 Day Range

MA: $7.18
Low: $5.92
High: $8.20

2 Week Range

Now: $7.96
Low: $3.75
High: $9.40

Volume

5,009 shs

Average Volume

17,567 shs

Market Capitalization

$36.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53